Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 283-810-9 | CAS number: 84713-17-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1998-01-13 to 1998-02-12
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1995
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Version / remarks:
- (1996)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2,2,4(or 2,4,4)-trimethylhexanedinitrile
- EC Number:
- 283-810-9
- EC Name:
- 2,2,4(or 2,4,4)-trimethylhexanedinitrile
- Cas Number:
- 84713-17-7
- Molecular formula:
- C9H14N2
- IUPAC Name:
- 2,2,4-trimethylhexanedinitrile; 2,4,4-trimethylhexanedinitrile
- Details on test material:
- 2,2,4(or 2,4,4)-Trimethylhexanedinitrile of Creanova Spezialchemie GmbH. Purity 96.5 % (GC-FID area), ID 0637/81824, produced January 1997.
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ORGANISMS
- Source: Harlan Winkelmann GmbH, 33176 Borchen (Germany)
- Age: 6-8 weeks
- Weight at study initiation: males mean 143 g, females mean 124 g
- Number of animals: 5 per dose group and sex, total 60 including satellite groups
- Diet: ad libitum, R10 special diet for rats, SSniff R
- Water: ad libitum, tap water
- Acclimation period: at least 5 days
ENVIRONMENTAL CONDITIONS
- Temperature: 22 +/- 3 °C
- Humidity: 30 - 705 %
- Photoperiod: 12 hours artificial light, 12 hours dark
- Air changes: 15 per hour
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on oral exposure:
- ADMINISTRATION / EXPOSURE
- Vehicle: Corn oil
- Concentration in vehicle: 0, 7.5, 25, or 75 mg/ml
- Total volume applied: 2 ml/kg bw/treatment
- dosing formulations were prepared weekly
- test substance and vehicle was homogenized by means of a magnetic stirrer for 15 minutes - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Concentrations of test substance and stability were determined by gas-liquid chromatography. Results showed a satisfactory concordance between
measured and nominal concentration and a stability over one week.
Homogenity of the samples was calculated by density-determination. The results showed that the samples were homogeneous. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
15; 50; 150 mg/(kg bw * d)
Basis:
other: nominal in corn oil
- No. of animals per sex per dose:
- 5 control and dosed groups
5 control satellite and high dose satellite - Control animals:
- yes, concurrent vehicle
- Details on study design:
- Post-exposure period: 2 days
SATELLITE GROUPS AND REASONS THEY WERE ADDED: Control (group 5) and high dose (group 6) satellite groups were treated similary to replace
control or high dose animals in case of mortalities in these groups. - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CLINICAL OBSERVATIONS AND FREQUENCY:
- Clinical signs: General observation once daily, considering the peak of anticipated effects after dosing; at weekends one hour after application.
- Mortality: Twice daily, preferably early morning and late afternoon
- Body weight: Days 0, 7, 14, 21, 28, 30.
- Food consumption: Once each week. Meaningful evaluation was not possible due to mortality in high dose males and females and medium
dose females.
- Water consumption: Daily
- Hematology: End of treatment: Red blood cell count (RBC); total white blood cell count (WBC); platelet count (PLT); hemoglobin (HGB);
hematocrit (HCT); erythrocyte mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC); differential white blood cellcount (granulocyte, lymphocyte, monocyte, plasmacyte); coagulation.
- Biochemistry: End of treatment: Sodium; potassium; calcium; aspartate aminotransferase (AST); alanine aminotransferase (ALT); alkaline
phosphatase (AP); glucose (GLUC); triglycerides (TRIG); cholesterol (CHOL); total bilirubin (TBIL); blood urea nitrogen (BUN); creatinine (CREA);
total protein (TPROT); albumin (ALB).
- Urinalysis: End of treatment: Volume (VOL); specific gravity (SPGR); pH; color. Semiquantitative: Protein (PROT); glucose (GLUC); keton;
urobilinogen (UBG); blood ingredients. Microscopical urine sediment analysis (all samples): Leucocytes (LEUCO); erythrocytes (ERY); bacteria
(BAC); epithelial cells, squamous (ECSQ) and renal (ECRE); oxalate crystals (OXA); triple phosphate crystals (TRIP); urate crystals (URA);
carbonate (CARB); granular cylinders (GRACYL); phosphate (PHOS). - Sacrifice and pathology:
- ORGANS EXAMINED AT NECROPSY (MACROSCOPIC AND MICROSCOPIC):
- Macroscopic: Complete autopsy of all animals that
(a) died during the study or
(b) survived in groups 1-4 and 6.
Weights of adrenals, brain, epididymides, heart, kidneys, liver, spleen, testes, thymus from animals of groups 1-4 (incl. substitutes of group 6).
- Microscopic: Kidney, liver, lung, gastrointestinal tract of all high dose animals which died during the study; selected additional samples. - Other examinations:
- OTHER EXAMINATIONS: Functional observational batteries (FOB) in home cage (HCO) and in open field (OFO) once each week, extended version in
the 4th week.
HCO parameters: Posture; coordination; tremor/convulsion; abnormal behavior.
OFO parameters: Behaviour; autonomic functions; fur; skin / appearance; muscle tone; posture; coordination; respiration; activity / attention; tremor / convulsion; abnormal behavior; eyes / palpepral closure; feces; urine.
Extended OFO parameters: Vision test; pupillary reflex; winking reflex; pinna-reflex; hearing test; sense of smell; examination of catalepsy;
coordination of movement; sensitivity to pain; rearing; grip strength; landing foot-splay test.
Motoractivity assessment in 4th week. - Statistics:
- STATISTICAL METHODS:
- Kruskal Wallis non parametric analysis of variance and in case of significance Wilcoxon, Mann, and Whitney U-test: Rearing; landing foot-splay;
grip strength; motoractivity; absolute body weights; body weight changes; absolute and relative organ weights; differential blood count; urine
analysis data.
- One way analysis of variance (ANOVA) incorporating a Bartlett's test for homogeneity of variance and in case of heterogeneous variances a
Kruskal Wallis test / in case of significant ANOVA a Scheffe test: Hematological data (except differential blood count) and serum clinical chemistry
data.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- NOAEL (NOEL), LOAEL (LOEL):
Oral adminstration of trimethyladiponitrile for a period of 28 days at dose levels of 150 and 50 mg/(kg bw * d) resulted in effects of toxicological importance. Administration of trimethyladiponitrile at a nominal dose level of 15 mg/(kg bw * d) caused no effects of toxicological importance. Therefore, under the experimental conditions, the NOAEL is 15 mg(kg bw * d).
ACTUAL DOSE RECEIVED BY DOSE LEVEL BY SEX
Throughout the study the analytical results showed a satisfactory concordance between measured and nominal concentrations (94.5 - 100 % recovery).
TOXIC RESPONSE/EFFECTS BY DOSE LEVEL:
- Mortality and time to death (first treatment = day 0):
medium dose: 1/5 females (day 18), 0/5 males
high dose: 4/10 females (days 5, 12, 13, 18), 5/10 males (days 1, 1, 6, 7, 9)
Time of death: Between day 1 and day 18, approximately 1/2 - 2 hours after applications.
- Clinical signs:
Control groups: No clinical signs of toxicological importance were observed.
Low dose group: No clinical signs of toxicological importance were observed.
Medium dose group: Squatting position, convulsions, increased activity, prone position and closed eyes were observed on some days of the
treatment period.
High dose groups: The same symptoms as in the medium dose group were observed more often and more severe.
- Body weight gain: No differences of toxicological importance were found in females. The male high dose group had a statistically significantly
(p<0.05) lower body weight gain (-23.8 %) and body weight during / after the first week. Both body weight gain and body weight remained below
those of the control throughout the study, but the differences were no longer statistically significant.
- Food/water consumption: No overt intergroup differences in food or water consumption were found. Determination of food consumption was
not possible in groups with mortalities.
- Clinical chemistry: No significant differences to controls were found in treated females. The male high dose group showed an increase of sodium
when compared with control, which was statistically significant but minor (+2.0 %) and within the historical controls.
- Hematology: Statistically significant findings were found in females and considered to be of toxicological importance:
Medium dose: Decrease of red blood cell count (-7.8 %), decrease of lymphocytes (-8.6 %)
High dose: Decrease of red blood cell count (-5.8 %), decrease of hemoglobin (-7.8 %)
- Urinalysis: The only statistically significant finding was an increase of pH in high (+1.9) and medium (+2.4) dose females, which was, however,
in the normal range and thus considered to be of minor toxicological importance.
- Organ weights: Changes in female liver weights and in male gonad and epididymis weights were considered to be of toxicological importance:
Liver weights were increased in medium (absolute +15 %; relative +11.8 %) and high dose (absolute +15 %; relative +11.5 %) females. Statistical
significance was found only for the medium group relative liver weights (p<0.05).
Absolute weights of gonads (-18 %) and epididymis (-28 %) were statistically significantly decreased in high dose males. The poor general
health state of the high-dose males might be an explanation for the reduced development of the male gonads.
Due to absence of a dose-relationship and a clear pattern, a statistically significant decrease in relative heart weight of medium dose
males (-7.3 %) was considered to be of no toxicological importance.
- Gross pathology: The macroscopical findings in treated and control animals consisted of lesions such as pelvic dilatation in the kidneys of one
male animal, sperm granuloma in five males and hydrometra in one female. The lung of individual animals of the different dose and control groups showed small foci (0.1 mm diameter). These findings were not dose-related. One male of the high dose group showed unilateral testis atrophy.
The lung of the animals which died during the study showed congestion and emphysema. The liver of three high dose animals (one male, two
females) showed an abnormal appearance and parts of the gastrointestinal tract of individual high dose male and female animals showed
hyperemic / hemorrhagic mucosa.
- Histopathology: Histopathological examination of animals of the high dose group revealed changes of toxicological importance predominantly in li ver (centrilobular vacuolation, one female: centrilobular hypertrophy) and kidney (tubular necrosis). Inflammatory foci in the lungs were not dose- related and most likely caused as part of a virus infection. They were not observed in animals that died during the study.
Histopathological examination of testes and epididymis in high-dose males showed no significant findings apart from the already macroscopically detected unilateral atrophy of testes and epididymis in one animal. The unilateral testes atrophy of this animal does not explain the significant
reduction of the group mean gonad weight because testes and epididymis of all animals in this group showed a decreased weight when compared
with control, low- or medium-dose group.
- Other: Functional observational batteries (FOB)
Home cage (HCO) and open field (OFO): Only mild clinical effects in individual animals of the high and medium dose groups were observed:
Minimal hyper-and hypoactivity, piloerection, eructation and hunchback/squatting position.
Extended OFO: Animals of all groups showed a normal response. Female and male animals of all dose groups showed no significant findings
concerning number or rearings, landing foot-splay test and grip strength when compared with controls.
Motoractivity assessment: Differences were minor and not dose-related in treated animals of both sexes.
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Effect level:
- 15 mg/kg bw/day (nominal)
- Basis for effect level:
- gross pathology
- haematology
- organ weights and organ / body weight ratios
- Dose descriptor:
- LOAEL
- Effect level:
- 50 mg/kg bw/day (nominal)
- Basis for effect level:
- haematology
- organ weights and organ / body weight ratios
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
no further remarks
Applicant's summary and conclusion
- Conclusions:
- Oral administration of 2,2,4(or 2,4,4)-trimethylhexanedinitrile to rats for a period of 28 days at dose levels of 150 and 50 mg/kg bodyweight resulted in effects of toxicological importance. Administration of 2,2,4(or 2,4,4)-trimethylhexanedinitrile at a nominal dose level of 15 mg/kg/day caused no effeccts of toxicological importance. Therefore, in our experimantal conditions, the no effect level (NOEL) is 15 mg/kg/day.
- Executive summary:
In this guideline study (OECD 407 (1995); 96/54/EC B.7) three groups of 5 male and 5 female Wistar rats, additional a control and a high dose satellite group each consisting of five males and females, were dosed with 15, 50, and 150 mg/kg/day 2,2,4(or 2,4,4)-trimethylhexanedinitrile once daily by oral gavage for 4 weeks. 2,2,4(or 2,4,4)-Trimethylhexanedinitrile treatment of 15 mg/kg/day caused no effects of toxicological importance. Administration of the test substance of 50 and 150 mg/kg/day caused clinical symptoms associated with a high mortality rate especially in high dose animals (only one medium dose female died). The high dose groups and the high dose satellite groups showed during the application period the clinical symptoms more often and more severe when compared with the medium dose group. Beside these clinical symptoms other effects of toxicological importance were noted in medium and especially in high dose animals. The high dose male group showed a slightly reduced bodyweight gain. Medium and high dose females showed a decrease of Red Blood Cell Count and high dose females showed also a decrease of Haemoglobin. The relative and absolute liver weights were increased in high and medium dose females. The male high dose group showed statistically significantly decreased weight of gonads and epididymides when compared with control. Macroscopical and especially histopathological examination revealed changes of toxicological importance predominantly in liver and kidney. Histopathological examination of testis and epididymis in high dose males showed no significant findings, apart from the already macroscopically detected unilateral atrophy of testis and epididymis in one animal. The unilateral testis atrophy of this animal does not explain the significant reduction of the group mean gonad weight because testis and epididymis of all animals in this group showed a decreased weight when compared with control, low or medium dose groups. The poor general health state of the high dose males might be an explanation for the reduced development of the male gonads.
Oral administration of 2,2,4(or 2,4,4)-trimethylhexanedinitrile to rats for a period of 28 days at dose levels of 150 and 50 mg/kg bodyweight resulted in effects of toxicological importance. Administration of 2,2,4(or 2,4,4)-trimethylhexanedinitrile at a nominal dose level of 15 mg/kg/day caused no effeccts of toxicological importance. Therefore, in our experimantal conditions, the no effect level (NOEL) is 15 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.